ICON plc, (NASDAQ: ICLR), a global provider of outsourced
development services to the pharmaceutical, biotechnology and medical
device industries, today announced that it has completed the previously
announced acquisition of Aptiv
Solutions.
Aptiv Solutions is a recognised leader in the design and execution of
adaptive clinical trials for pharmaceutical and biotech customers. The
company also has in-depth experience in the management of medical device
trials and its Japanese subsidiary, Niphix, is a full-service,
oncology-focused CRO serving both Japanese and international customers.
“Aptiv’s adaptive trial capabilities, combined with our existing
technology platforms, such as ICONIK and Firecrest, will further
differentiate our services and help our customers take time and cost out
of the development process,” commented Dr. Nuala Murphy, President,
ICON Clinical Research Services. “Their presence in Japan and medical
device capabilities will also broaden our offerings in these markets.”
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
About ICON plc
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The company
specialises in the strategic development, management and analysis of
programs that support clinical development - from compound selection to
Phase I-IV clinical studies. ICON currently has approximately 10,300
employees, operating from 76 locations in 37 countries.
Further information is available at www.iconplc.com
ICON/ICLR-F
Copyright Business Wire 2014